Exploring High Growth Tech Stocks In United States October 2024
In This Article:
Over the last 7 days, the United States market has remained flat, yet it is up 38% over the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with current market trends but also demonstrate strong potential for sustained revenue and earnings expansion.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 20.86% | 27.98% | ★★★★★★ |
| Sarepta Therapeutics | 23.67% | 43.83% | ★★★★★★ |
| TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
| Invivyd | 42.91% | 70.39% | ★★★★★★ |
| Ardelyx | 27.19% | 66.44% | ★★★★★★ |
| AsiaFIN Holdings | 60.53% | 81.55% | ★★★★★★ |
| Amicus Therapeutics | 20.33% | 62.45% | ★★★★★★ |
| Travere Therapeutics | 27.74% | 70.00% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
TeraWulf
Simply Wall St Growth Rating: ★★★★★☆
Overview: TeraWulf Inc. is a digital asset technology company operating in the United States, with a market capitalization of $2 billion.
Operations: TeraWulf generates revenue primarily through digital currency mining, reporting $120.25 million in this segment.
TeraWulf, navigating the volatile terrain of high-growth tech, has shown a promising trajectory with a forecasted revenue growth of 53% per year. This figure notably outpaces the broader US market's growth rate of 8.9%. Despite current unprofitability, earnings are expected to surge by 108.47% annually, positioning TeraWulf on a path towards profitability within three years. Recent strategic moves like the expanded Lake Mariner lease underscore its commitment to scaling operations in high-performance computing and AI data centers, ensuring long-term sustainability and aligning closely with industry shifts towards more energy-efficient digital infrastructure.
-
Take a closer look at TeraWulf's potential here in our health report.
-
Review our historical performance report to gain insights into TeraWulf's's past performance.
Sarepta Therapeutics
Simply Wall St Growth Rating: ★★★★★★
Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases, with a market cap of $12.12 billion.
Operations: Sarepta Therapeutics generates revenue primarily from discovering, developing, manufacturing, and delivering therapies, amounting to $1.50 billion. The company is focused on RNA-targeted therapeutics and gene therapies for rare diseases.